AstraZeneca Plc is to pay up to $1.15 billion to acquire privately-held Pearl Therapeutics Inc of the US which has a Phase 3 product in development for chronic obstructive pulmonary disease, as well as inhaler and formulation technology with potential application in future combination products.
Cardio3 BioSciences SA of Belgium has announced plans to raise new funds through an initial public offering of its shares on the NYSE Euronext exchanges in both Brussels and Paris. The company has a cell therapy for heart repair in Phase 3.
MorphoSys AG has successfully outlicensed its first proprietary antibody, MOR103 for rheumatoid arthritis, to GlaxoSmithKline Plc in a deal potentially valued at €445.5 million. The German company is set to receive an upfront payment of €22.5 million.
Horizon Discovery Ltd has announced the final closing of its Series C funding round with share placements valued at £6.9 million. The total sum raised in the round is £18.2 million which will be used to advance its research tools including cell lines.
GlaxoSmithKline Plc has paid €250 million in cash for the Switzerland-based vaccine company, Okairos AG, which has developed technology applicable to both prophylactic and therapeutic vaccine products.
Prosensa Holding BV of the Netherlands, which is developing an antisense oligonucleotide for Duchenne muscular dystrophy, has made a filing with the US Securities and Exchange Commission for a proposed initial public share offering.
Ugichem GmbH of Austria, which has developed a new antisense drug technology platform, has raised €2.25 million from public and private investors to advance preclinical drug candidates for immune-mediated inflammatory diseases.
AstraZeneca Plc is to pay up to $443 million to acquire Omthera Pharmaceuticals Inc of Princeton, New Jersey, a five-year-old company with a single product – a late stage omega-3 free fatty acid composition to treat hypertriglyceridaemia.
Roche has announced a new collaboration with Macrocyclics, a member of the Areva group, to continue development of a novel chelating agent for use in radioimmunotherapy. This is the second collaboration between the two companies.
Advanced Accelerator Applications (AAA) SA of France has raised €4.8 million in a placement of its shares with existing and new investors in order to finance an expansion of its manufacturing capacity for radioactive agents for Positron Emission Tomography (PET) imaging. Funds will also be used to investigate a second indication for the company’s radiopharmaceutical for cancer, Lutathera.